This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Thalassemia (Cooley's Anemia) Clinical Research Network (TCRN)

This study has been completed.
National Heart, Lung, and Blood Institute (NHLBI)
Thalassemia Clinical Research Network
Information provided by:
New England Research Institutes Identifier:
First received: October 27, 1999
Last updated: March 3, 2014
Last verified: July 2006
The purpose of the TCRN is to accelerate research in the management of thalassemia, standardize existing treatments, and evaluate new ones in a network of clinical centers in North America. The emphasis will be on clinical trials that help identify optimal therapy. Therapeutic trials may involve investigational drugs, drugs already approved but not currently used, and drugs currently used.

Condition Intervention
Anemia, Cooley's Beta-Thalassemia Hematologic Diseases Thalassemia Osteoporosis Iron Overload Hypertension, Pulmonary Drug: Deferoxamine Drug: Deferiprone Drug: Arginine Drug: Sildenafil Drug: Decitabine

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Thalassemia Clinical Research Network (TCRN)

Resource links provided by NLM:

Further study details as provided by New England Research Institutes:

Primary Outcome Measures:
  • Vary by protocol

Estimated Enrollment: 1000
Study Start Date: July 2000
Study Completion Date: July 2006
  Show Detailed Description


Ages Eligible for Study:   1 Year to 75 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Please refer to specific studies for eligibility criteria.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00000623

United States, California
Children's Hospital Oakland
Oakland, California, United States, 94609
United States, Massachusetts
Children's Hospital
Boston, Massachusetts, United States, 02115
United States, New York
Weill Medical College of Cornell University
New York, New York, United States, 10021
United States, Pennsylvania
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States, 19104
Canada, Ontario
Toronto General Hospital
Toronto, Ontario, Canada, M5G 2C4
Sponsors and Collaborators
New England Research Institutes
National Heart, Lung, and Blood Institute (NHLBI)
Thalassemia Clinical Research Network
Principal Investigator: Alan R. Cohen, MD Children's Hospital of Philadelphia
Principal Investigator: Patricia J. Giardina, MD Weill Medical College of Cornell University
Principal Investigator: Ellis J. Neufeld, MD, PhD Children's Hospital Medical Center, Cincinnati
Principal Investigator: Nancy F. Olivieri, MD Toronto General Hospital
Principal Investigator: Elliott P. Vichinsky, MD Children's Hospital & Research Center Oakland
Principal Investigator: Sonja McKinlay, PhD New England Research Institutes, Inc.
  More Information

Publications: Identifier: NCT00000623     History of Changes
Other Study ID Numbers: 317
U01HL065232 ( U.S. NIH Grant/Contract )
U01HL065233 ( U.S. NIH Grant/Contract )
U01HL065238 ( U.S. NIH Grant/Contract )
U01HL065239 ( U.S. NIH Grant/Contract )
U01HL065244 ( U.S. NIH Grant/Contract )
U01HL065260 ( U.S. NIH Grant/Contract )
Study First Received: October 27, 1999
Last Updated: March 3, 2014

Keywords provided by New England Research Institutes:

Additional relevant MeSH terms:
Iron Overload
Hematologic Diseases
Hypertension, Pulmonary
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Genetic Diseases, Inborn
Iron Metabolism Disorders
Metabolic Diseases
Lung Diseases
Respiratory Tract Diseases
Sildenafil Citrate
Vasodilator Agents
Phosphodiesterase 5 Inhibitors
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Urological Agents
Antimetabolites, Antineoplastic
Antimetabolites processed this record on September 20, 2017